Public popular science and science communication! Click the blue wordone click to follow
On May 18, the first “treatment report” of the domestically produced new crown oral drug was announced. The paper shows that: 5 infected persons received the oral drug within 3 days after the nucleic acid test was positive. The number is 11.13 days. In terms of data alone, early treatment and early medication may halve the treatment cycle.
Relevant research was carried out by the National Center for Infectious Diseases Medicine, Professor Zhang Wenhong, Director of the Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University, and the team of Professor Fan Xiaohong from Shanghai Public Health Clinical Center, etc. The effect of a domestic oral drug named VV116 on the nucleic acid conversion time of non-severe Omicron-infected patients. Detailed data from the study were published online May 18 in the journal Emerging Microbes & Infections.
What is VV116?
VV116 is an oral anti-coronavirus drug developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences and other institutes in cooperation with enterprises.
Relevant R&D units previously disclosed that Shen Jingshan, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and other teams found in experiments on an adenovirus mouse model that oral administration of VV116 could reduce the virus titer Below the detection limit, and significantly improve the pathological changes in the lung tissue of experimental model animals, the drug was approved for the treatment of new crowns in Uzbekistan at the end of last year, and has been approved for clinical trials in China.
The industry is more optimistic about VV116 and believes that it has the potential to become an effective drug for the treatment of the new crown. Relevant experts explained in previous interviews with Science and Technology Daily that the basic principle of VV116 attacking the new coronavirus is similar to that of Remdesivir. It is the core enzyme for attacking the new coronavirus. The greater advantage of VV116 is that it can be taken orally.
When the new coronavirus is self-synthesizing in the human body, VV116 can disguise “adulteration”, making the RNA polymerase of the new coronavirus “stuck” and unable to replicate in the human body.
Studies suggest that administration within 5 days after positive is critical
In the study, 136 COVID-19 patients were divided into two groups according to their own wishes: 60 received the domestically produced COVID-19 oral drug VV116, 300 mg of VV116 orally every 12 hours; 76 were included in the control group without antiviral therapy . Both groups of participants will receive anti-inflammatory and other symptomatic treatment.
The data shows that the time of nucleic acid conversion to negative nucleic acid was 8.56 days for patients infected with Omicron who used VV116 within 5 days of the first nucleic acid test positive, which was less than 11.13 days for the control group. to the latter.
and if the drug is not taken in time after positive, the effect of the drug will be difficult to show. The specific data are as follows: the time of nucleic acid conversion to negative was 11.46 days for patients infected with Omicron who used VV116 5 days after the first nucleic acid test was positive, and the control group was 11.13 days, and the two were almost the same.
The data show that administration within 5 days will lead to greater benefit for patients. This pattern did not appear in VV116, and it was also suggested in studies related to approved new crown drugs (such as monupavir and paciclovir). It can be seen that early treatment and early intervention will greatly shorten the infection time.
The study also collected data on the drug safety of VV116. The results showed that there were no serious adverse events, 7 cases reported mild abnormal liver function, 1 case reported increased blood urea, and 1 case of increased white blood cell count, all of which were relieved and recovered without intervention.
Small-molecule drugs or better protection against mutations
Omicron variants become Since the mainstream strain of the new crown pandemic, multiple studies have shown that mutant strains can successfully escape the neutralizing antibody drugs that have been developed.
For example, a paper published in the journal Nature late last year evaluated 9 neutralizing antibodies at the time, showing that 5 were completely ineffective and 2 had reduced effective activity. 20 times.
A previous study by Zhang Wenhong’s team compared the neutralizing abilities of 20 neutralizing antibodies against Omicron, Omicron sublines and different variant sites Changes, suggesting that a large number of neutralizing antibodies are or have “successfully escaped by the virus”. Although a small number of antibodies have not escaped, given the mutagenic nature of RNA viruses (the new coronavirus is an RNA virus), drug resistance may develop if it is administered long-term as a monotherapy, the researchers said.
Under such premise, small molecule anti-new coronavirus drugs have high hopes. The good news is that more and more small-molecule antiviral drugs have been shown to remain effective against variants of the new coronavirus, such as Pacyclovir, which has been approved for marketing, and VV116, which is reported today.
Source: Science and Technology Daily
Support us please Share ☟☟☟< /p>
Public ID: Science_China
Public Science Communication< /span>
Official WeChat of China Association for Science and TechnologyLetter National Science Popularization Platform
Long press to identify the QR code on the left, follow us